No Racial Disparities In Surgical Care Quality Observed After Coronary Artery Bypass Grafting In TRICARE Patients

Health Aff (Millwood). 2019 Aug;38(8):1307-1312. doi: 10.1377/hlthaff.2019.00265.

Abstract

In the US, racial disparities in outcomes following coronary artery bypass grafting (CABG) are well documented. TRICARE insurance data represent a large population with universal insurance that allows for the robust assessment of the impact of such insurance on disparities in health care. This study examined racial differences in specific aspects of surgical care quality following CABG, using metrics endorsed by the National Quality Forum that included the prescription of beta-blockers and statins at discharge and thirty-day readmissions. There were no risk-adjusted differences in outcomes between African American and white patients insured through TRICARE. Our study provides a window into the potential impacts of universal insurance and an equal-access health care system on racial disparities in surgical care quality following CABG.

Keywords: Healthcare Insurance; Universal Healthcare; racial disparities.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Black or African American / statistics & numerical data
  • Coronary Artery Bypass / standards*
  • Coronary Artery Bypass / statistics & numerical data
  • Coronary Disease / prevention & control
  • Coronary Disease / surgery
  • Female
  • Healthcare Disparities / ethnology
  • Healthcare Disparities / statistics & numerical data*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Military Health Services / standards*
  • Military Health Services / statistics & numerical data
  • Patient Readmission / statistics & numerical data
  • Quality Indicators, Health Care
  • Racial Groups / statistics & numerical data*
  • United States
  • White People / statistics & numerical data

Substances

  • Adrenergic beta-Antagonists
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors